Ranking Invest

Longboard Pharmaceuticals, Inc.

Segmento: Healthcare Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

Indicadores Básicos

Valor de Mercado

$ 2.34 Bi

IVR

0.04

IVR2

-0.08

Índices de Previsibilidade

Faturamento

0.00

Lucro

0.16

Margem

0.00

Índices de Tendência

Faturamento

0.00

Lucro

-10.44

Margem

0.00

Índices de Endividamento

DIV/PAT

-0.09

DIV/L4T

0.31

Dívida Líquida

-$ 23.88 Mi

Patrimônio Líquido

$ 275.19 Mi

L4T

-$ 76.34 Mi

MM4T

-46978.13%

Dívidas
Dividendos
Cotação: $59.98

Não há dados de histórico de dividendos para exibir.

Gráfico Lucro/Faturamento X Trimestre